JCR Pharmaceuticals enters another deal with Alexion
Japanese drugmaker JCR Pharmaceuticals (TYO: 4552) saw its shares dip 1.75% to 1,121 yen today, despite news of a second deal with Alexion.
JCR has signed a research collaboration, option and license agreement with the AstraZeneca (LSE: AZN) rare diseases subsidiary for the development of novel oligonucleotide therapeutics to support targeted delivery to certain tissues or organs using J-Brain Cargo, JCR’s proprietary blood-brain barrier (BBB)-penetrating technology.
Under the terms of the accord, JCR and Alexion will research and develop oligonucleotide therapeutics using J-Brain Cargo Technology. As part of the collaboration, Alexion can nominate up to three targets in rare disease indications for pre-clinical development using the platform. Following pre-clinical development, Alexion will have the option to develop and commercialize the potential new drug candidates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze